Recent News

• 06.11.2025 - Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
• 06.11.2025 - Capricor Therapeutics Announces Key Regulatory Updates for its Duchenne Muscular Dystrophy Program
• 05.13.2025 - Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.13.2025 - Capricor Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.13.2025 - Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
• 05.13.2025 - Capricor Therapeutics Appoints Michael Binks, M.D. as Chief Medical Officer
• 05.06.2025 - Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
• 05.06.2025 - Capricor Therapeutics to Present First Quarter 2025 Financial Results and Recent Corporate Update on May 13
• 05.05.2025 - Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
• 05.05.2025 - Capricor Therapeutics Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Recent Filings

• 05.27.2025 - 8-K Current report
• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 8-K Current report
• 04.30.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 04.09.2025 - ARS Annual Report to Security Holders
• 04.08.2025 - DEF 14A Other definitive proxy statements
• 04.08.2025 - 8-K Current report